GENFIT Reports Fourth Quarter 2025 Financial Information and Provides a Corporate Update

Cash and cash equivalents totaled €101.1 million as of December 31, 2025Revenues amounted to €65.4 million as of December 31, 2025Ipsen’s strong performance with Iqirvo® in PBC (>$200M net sales in year one) triggered GENFIT’s €17.0 million ($20.0 million) milestone, included in reported revenues, but not yet reflected in the cash positionACLF and CCA programs progressing according to plan Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), February 26, 2026 - GENFIT (Euronext: G ...